CC-90005

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ) , with an IC 50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC 50 =4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2 expression In Vitro CC-90005 shows the exquisite selectivity of CC-90005, with IC 50 s for all other family members of >3 μM. CC-90005 is a moderate inhibitor of both CYP2C9 (IC 50 =8 μM) and CYP2C19 (IC 50 =5.9 μM) in human liver microsomes. CC-90005 inhibits IL-2 expression in LRS_WBC human PBMCs, with an IC 50 of 0.15 μM. CC-90005 (1-10 μM; 24 h) inhibits T cell proliferation in PBMCs by 51% at 1 μM and 88% at 3 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CC-90005 (3-30 mg/kg; p.o. twice daily for 4 days) significantly reduces the popliteal lymph node (PLN) size in a model of chronic T cell activation . CC-90005 (100 mg/kg; a single p.o.) significantly inhibits plasma and spleen IL-2 release by 51 and 54%, respectively . CC-90005 exhibits reasonable oral bioavailability (66 and 46%) and C max (1.18 and 1.2 μM) following oral administration (10 and 3 mg/kg) in rat and dog, respectively . CC-90005 exhibits the mean residence time (0.52 and 2.0 h), CL (69.1 and 20.5 mL/min/kg) and Vss (2.11 and 2.44 L/kg) following intravenous administration (2 and 1 mg/kg) in rat and dog, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: B6D2F1 mice (20 g) were injected with allogeneic spleen cells Dosage: 3, 10, 30 mg/kg Administration: P.o. twice daily for 4 days Result: Inhibited PLN size by 45 and 38% at doses of 10 and 30 mg/kg, respectively. Form:Solid IC50& Target:PKCθ 8 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet